Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 604

1.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

2.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.

Eur Respir J. 2007 Mar;29(3):469-75. Epub 2006 Nov 1.

4.

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

McLaughlin VV.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5.

PMID:
16919005
5.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
6.
7.

Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.

Porhownik NR, Myers R, Bshouty Z.

Can Respir J. 2013 Mar-Apr;20(2):111-5.

8.

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.

Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.

Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490. Review.

9.

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:32-8.

PMID:
16919008
10.

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. doi: 10.1093/rheumatology/kep107. Review.

11.

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G.

Eur Heart J. 2006 Mar;27(5):589-95. Epub 2006 Jan 23.

12.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2012 Feb;31(2):150-8. doi: 10.1016/j.healun.2011.11.002. Epub 2011 Dec 3.

PMID:
22138355
13.

Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.

D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.

Int J Cardiol. 2012 Mar 22;155(3):378-82. doi: 10.1016/j.ijcard.2010.10.051. Epub 2010 Nov 16.

PMID:
21081251
14.
15.

Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.

PMID:
18022071
16.

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.

Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:25-31.

PMID:
16919007
17.

[Pulmonary arterial hypertension and systemic sclerosis].

Launay D, Humbert M, Hachulla E.

Presse Med. 2006 Dec;35(12 Pt 2):1929-37. Review. French.

PMID:
17159719
18.

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.

Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.

J Heart Lung Transplant. 2011 Dec;30(12):1327-33. doi: 10.1016/j.healun.2011.08.019.

PMID:
22055098
19.

Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.

Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:49-53.

PMID:
16919011
20.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk